Last mentioned: Feb 21, 2026
Q4 2025 Earnings
Both companies report record performance and optimistic 2026 outlooks.
Payer Milestone
Talkspace surpasses 140 million covered lives through payer partnerships.
Talkspace Profitability
Talkspace achieves its first full quarter of adjusted EBITDA profitability.
Commercial Launch
Initial rollout of iDose TR begins in the U.S. market with targeted accounts.
iDose TR FDA Approval
Glaukos receives landmark approval for its travoprost intracameral implant.
Glaukos Corporation reported strong Q4 2025 results, driven by the rapid commercial adoption of its iDose TR sustained-release implant and a resilient MIGS franchise. The company's strategic shift toward dropless glaucoma therapies is yielding significant revenue growth and improved 2026 guidance.
Glaukos Corporation and Talkspace, Inc. reported strong Q4 2025 financial results, highlighting a successful transition toward high-margin, recurring revenue models. Glaukos saw significant gains from its iDose TR launch, while Talkspace solidified its position as a profitable, payer-led behavioral health leader.